Abstract
The association between hypothyroidism and non-alcoholic steatohepatitis (NASH) is characterized by elevated plasma reverse T3 (RT3), low T3/RT3 ratio and deficient hepatic fat and cholesterol metabolism. Resmetirom (MGL-3196) is a liver-directed, oral selective thyroid hormone receptor-β agonist that reduces MRI-PDFF, fibrosis, atherogenic lipids and hepatic inflammation. MAESTRO-NAFLD is a 52-week randomized double-blind placebo-controlled phase 3 clinical trial to study the effect of resmetirom on non-invasive biomarkers and imaging (NCT04197479).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
